European Study to Describe Hospital Stay in Patients Admitted for Acute Bipolar Manic Episodes

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01239589
First received: November 10, 2010
Last updated: March 28, 2011
Last verified: March 2011

November 10, 2010
March 28, 2011
November 2010
March 2011   (final data collection date for primary outcome measure)
Length of hospital stay [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01239589 on ClinicalTrials.gov Archive Site
  • Use of resources [ Designated as safety issue: No ]
  • Treatments used [ Designated as safety issue: No ]
  • Demographics [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
European Study to Describe Hospital Stay in Patients Admitted for Acute Bipolar Manic Episodes
European Study to Describe Hospital Stay in Patients Admitted for Acute Bipolar Manic Episodes Treated With Immediate Release Quetiapine or Extended Release Quetiapine

This study is being carried out to find out how patients suffering from the acute manic phase of bipolar disease are currently managed with Quetiapine Immediate Release (IR) or Quetiapine Extended Release (XR) in the hospital setting in real life practice, including length of stay.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample

Patients diagnosed with Bipolar Disorder (ICD-10).admitted due to a acute manic episode and treated with quetiapine IR or quetiapine XR during the hospitalization period

Acute Bipolar Manic Episode
Not Provided
  • 1
    patients admitted as for an acute bipolar manic episode and treated with quetiapine IR
  • 2
    patients admitted as for an acute bipolar manic episode and treated with quetiapine XR
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1280
March 2011
March 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients diagnosed with Bipolar Disorder (ICD-10).
  • Admitted for acute bipolar manic episode from 1st October 2009 to 1st October 2010
  • Patients treated with quetiapine IR or quetiapine XR during the hospitalization period.

Exclusion Criteria:

  • Patients in which BD is not the main reason for hospitalization
  • Patients admitted for acute bipolar mania episodes but finally diagnosed with mixed or bipolar disorder not otherwise specified (NOS) episodes
  • Patients receiving both quetiapine IR and XR during the same hospitalization period.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Italy,   Belgium,   Croatia,   Denmark,   Finland,   Germany,   United Kingdom,   Turkey
 
NCT01239589
NIS-NEU-SER-2010/1
No
Medical Science Director, AstraZeneca
AstraZeneca
Not Provided
Not Provided
AstraZeneca
March 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP